Some of Wednesday's midday movers:» Read More
*Pfizer to discuss favorable data with FDA. Feb 3- Pfizer Inc's experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study's primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.
Feb 3- Pfizer Inc's experimental breast cancer drug significantly improved patient survival rates in a mid-stage trial without their condition worsening, maintaining the company's lead in the race for a new treatment standard for the disease.
*Sanofi alleges Lilly infringed four patents. *Sanofi, Novo shares rise on delayed biosimilar threat. NEW YORK/ PARIS, Jan 31- French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. firm's plans to produce a copycat version of Lantus.
Jan 30- French drugmaker Sanofi sued Eli Lilly and Co on Thursday, alleging that the U.S. pharmaceutical company infringed patents on its top-selling diabetes treatment, the insulin product Lantus.
Treasurys held on to earlier losses after of the Treasury Dept's auction of five-year notes and seven-year debt and after the release of US GDP data.
U.S. stock index futures traded higher on Thursday, on what will be the busiest day of fourth quarter earnings season.
Some of the names on the move ahead of the open.
Eli Lilly reported sales well above Street expectations, although overall revenue declined due to generic competition for Cymbalta.
Eli Lilly Chairman & CEO John Lechleiter discusses the productivity in its labs to find new medicines, and how the Affordable Care Act is impacting his business.
Jan 30- Eli Lilly and Co reported quarterly revenue well above Wall Street expectations, although overall revenue declined due to generic competition for the company's Cymbalta depression treatment. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring.
Jan 29- After three years of seeing major drugs like Zyprexa for schizophrenia lose patent protection and wipe away billions of dollars in revenue, Eli Lilly and Co Chief Executive Officer John Lechleiter wants to change the game plan.
Jan 28- Pfizer Inc reported better-than-expected fourth-quarter results, helped by higher sales of drugs for cancer, nerve pain and arthritis, and forecast 2014 earnings in line with Wall Street estimates.
LONDON, Jan 24- GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. Albiglutide belongs to the same class of injectable GLP-1 drugs as Victoza from Novo Nordisk, as well as Byetta and Bydureon from Bristol-Myers Squibb and AstraZeneca.
NEW YORK, Jan 21- David Blech, once dubbed the "King of Biotech", failed to persuade a U.S. appeals court to throw out his four-year prison term for securities fraud on the ground that his sentencing judge was biased.
The "Fast Money" traders share their final trades of the day.
WASHINGTON, Jan 14- The U.S. Food and Drug Administration appears skeptical that data submitted by Johnson& Johnson proves its anticoagulant Xarelto is effective in reducing the risk of further heart problems in patients who have recently suffered a heart attack.
COPENHAGEN, Jan 14- Danish biotech company Genmab has entered into a research collaboration with U.S. pharmaceutical company Eli Lilly involving its DuoBody technology platform.
*Novartis may swap animal health, vaccines for Merck's OTC. *Novartis, Merck may each trade $5 bln in assets- Bloomberg. LONDON/ FRANKFURT, Jan 9- Novartis AG is discussing swapping its animal health and human vaccines businesses for Merck& Co Inc's over-the-counter products unit in a deal that could boost earnings at both companies.
ZURICH, Jan 8- Swiss drugmaker Roche has found an efficient way for complex antibody drugs to reach and penetrate the brain, raising the possibility of more effective treatments for diseases such as Alzheimer's.
Some of Tuesday's midday movers: